NASDAQ:ELTX Elicio Therapeutics Q3 2026 Earnings Date & Estimates $1.78 -0.01 (-0.56%) Closing price 04:00 PM EasternExtended Trading$1.85 +0.07 (+3.93%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Elicio Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Elicio Therapeutics in Q3 2026Elicio Therapeutics is expected to post earnings of -$0.44 per share. In the same quarter a year earlier Elicio Therapeutics reported -$0.60 per share. Elicio Therapeutics last reported on August 13, 2026, posting -$0.43 per share and beating the -$0.5375 consensus estimate. Elicio Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.44Prior-Year EPS-$0.60Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.43 (Beat by +$0.1075)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Elicio Therapeutics Q3 2026 Earnings FAQ When does Elicio Therapeutics report Q3 2026 earnings? Elicio Therapeutics (NASDAQ:ELTX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Elicio Therapeutics' Q3 2026 earnings call? Elicio Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Elicio Therapeutics? Analysts expect Elicio Therapeutics to post earnings of -$0.44 per share for Q3 2026. Elicio Therapeutics Earnings HeadlinesElicio Therapeutics Inc ELTXOctober 14 at 9:03 PM | morningstar.comMElicio Therapeutics consensus price target lowered by 31.67% to $13.94October 3, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 15 at 1:00 AM | Porter & Company (Ad)B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy RatingSeptember 25, 2026 | finance.yahoo.comElicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026September 24, 2026 | globenewswire.comElicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from S&P Global BMI IndexSeptember 21, 2026 | marketscreener.comMSee More Elicio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email. Email Address About Elicio TherapeuticsElicio Therapeutics (NASDAQ:ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to treat cancer by directing immune responses to the lymph nodes, where key immune cells are activated. The company’s technology is based on its Amphiphile platform, which is intended to improve the delivery and activity of therapeutic vaccines and other immune-modulating agents. Elicio’s lead program is ELI-002, an investigational therapeutic cancer vaccine designed to target common KRAS mutations. The program is being evaluated in patients with KRAS-mutated solid tumors, including pancreatic and colorectal cancers. ELI-002 is intended to stimulate T-cell responses against residual disease and tumor cells carrying these mutations. The company is also advancing additional vaccine-based immunotherapies aimed at cancer-associated targets and personalized tumor antigens. Elicio Therapeutics was formerly known as Vedantra Pharmaceuticals and has focused on developing therapies intended to harness the immune system against cancer. Its products remain investigational and are not approved for commercial use.View Elicio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
